Company Snapshot
- Ticker
- DGX
- Name
- DGX
- Sector
- None
- Currency
- 0
- Relative Volume
- None
- Market Cap
- 20446720000.000000
- Volume
- 1,138,995
- Avg Volume (3M)
- 963,281
DGX
DGX
Last update recent
182.56
+0.99
(+0.55%)
Market Cap
20446720000.000000
Dividend Yield
0.00%
1Y Return
None%
Beta
None
Price & Moving Averages
Interactive chart with SMA overlays and intraday breadth.
Profitability
- Revenue
- 10850000000.000000
- EPS
- 8.64
- Dividend / Share
- None
- Total Dividends
- $0.00
- Dividend Yield
- 1.7%
- Net Income
- 969000000.000000
- Net Margin
- 8.93%
- Payout Ratio
- 35.81%
- Qtly Growth YoY
- None
Valuation & Quality
- P/E
- 21.10
- Forward P/E
- None
- P/S
- 1.88
- P/B
- 2.77
- Beta
- None
- Debt / Equity
- 0.87
- Current Ratio
- 1.13
- Return on Equity
- 0.13%
- Return on Assets
- 0.06%
Technicals & Returns
- Distance vs 200 DMA
- 3.75%
- 200 DMA
- 175.97
- Distance vs 50 DMA
- -0.45%
- 50 DMA
- 183.38
- Return 1Y
- None%
- Return YTD
- None%
- Beta (Trailing)
- None
- Relative Volume
- None
Factor Lens
Plot valuation, momentum, or volume trends.
Seasonal Performance
Company Overview
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct Read more
- Name
- DGX
- Industry
- Medical - Diagnostics & Research
- CEO
- Mr. James E. Davis
- Employees
- 50,000
- IPO Date
- 1996-12-17
- Phone
- 973 520 2700
- Address
- None
- Website
- https://www.questdiagnostics.com
Dividend Yield
0.00%
TTM Distributions
$0.00
Last Payout
2024-10-04 • $0.75
Latest News
Curated headlines from premium sources.
Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics Incorporated (DGX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Quest Diagnostics Incorporated (DGX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Octave Bioscience Forms Strategic Collaboration with Quest Diagnostics to Expand Patient Access to the Octave® Multiple Sclerosis Disease Activity (MSDA) Test Across the United States
MENLO PARK, Calif.--(BUSINESS WIRE)-- #MSCare--Octave Bioscience, a commercial-stage precision care company pioneering a new standard for managing multiple scl…
Advisors Asset Management Inc. Reduces Stock Position in Quest Diagnostics Incorporated $DGX
Advisors Asset Management Inc. cut its holdings in Quest Diagnostics Incorporated (NYSE: DGX) by 27.6% during the undefined quarter, according to its most rece…
Quest Diagnostics Incorporated $DGX Shares Acquired by Charles Schwab Investment Management Inc.
Charles Schwab Investment Management Inc. increased its position in shares of Quest Diagnostics Incorporated (NYSE: DGX) by 0.8% in the undefined quarter, acco…
HOLX vs. DGX: Which Healthcare Diagnostics Stock Is the Better Bet?
DGX's strong YTD gains and momentum in advanced diagnostics and acquisitions highlight why it may stand out in the competitive testing market against HOLX.